PK/PD evaluations of the novel atypical opioid tapentadol in red-eared slider turtles

• Autorzy: Giorgi M. , De Vito V. , Owen H. , Demontis M. P. , Varoni M. V.
• Języki publikacji: EN

Abstrakty

EN

The aim of this study was to evaluate the pharmacokinetics and pharmacodynamics of tapentadol (TAP) in red-eared slider turtles after a single intramuscular injection of 5 mg/kg. Turtles (n = 9) were randomly assigned to two treatment groups, according to an open, single-dose, single-treatment, unpaired, two-period crossover design. Group A (n = 5) received a single IM dose of TAP (5 mg/mL) at 5 mg/kg. Group B (n = 4) received a single IM injection of saline (equivalent to the opioid in volume). After a one-month wash-out period, the groups were rotated, and the experiment was repeated. TAP plasma concentrations were evaluated by a validated HPLC-FL method, while an infrared thermal stimulus was applied to the plantar surface of the turtles’ hind limbs to evaluate the thermal withdrawal latency (TWL). TAP plasma concentrations were detectable between 1 and 24 h (2141 – 42 ng/mL, respectively). The TAP-treated group showed a dramatic increase in TWL one hour after drug administration (15.31 ± 4.73 s). Subsequently, TWL decreased with time. Significant differences between the treatment and control groups were apparent up to 10 h following treatment. A linear relationship (r2 = 0.98) between the TAP plasma concentration and effect was found. Given these qualities, TAP appears to be an attractive option for antinociception in turtles because of its rapid onset and acceptable duration of effect.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2014
• Tom: 70
• Numer: 09
• Opis fizyczny: p.530-535,fig.,ref.

Twórcy

autor

Giorgi M.

• Department of Veterinary Sciences, University of Pisa, Via Livornese (lato monte) 1, San Piero a Grado, Pisa, Italy

autor

De Vito V.

• Department of Veterinary Sciences, University of Pisa, Via Livornese (lato monte) 1, San Piero a Grado, Pisa, Italy

autor

Owen H.

• School of Veterinary Sciences, University of Queensland, Gatton, Brisbane, Australia

autor

Demontis M. P.

• Department of Dipartimento di Medicina Veterinaria, Universita di Sassari, Sassari, Italy

autor

Varoni M. V.

• Department of Dipartimento di Medicina Veterinaria, Universita di Sassari, Sassari, Italy

Bibliografia

• 1. Baker B. B., Sladky K. K., Johnson S. M.: Evaluation of the analgesic effects of oral and subcutaneous tramadol administration in red-eared slider turtles. JAVMA 2011, 238, 220-227.
• 2. Berner N. J.: Oxygen consumption by mitochondria from an endotherm and an ectotherm. Comp. Biochem. Physiol. Part B 1999, 124, 25-31.
• 3. Dirig D. M., Salami A., Rathbun M. L., Ozaki G. T., Yaksh T. L.: Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli. J. Neurosci. Meth. 1997, 76, 183-191.
• 4. Duke-Novakovski T.: Opioids, [in:] Egger C. M., Love L., Doherty T. (ed): Pain Management in Veterinary Practice, First Ed. Wiley-Blackwell, Ames, IA, USA 2013, pp. 41-68.
• 5. Fejős I., He Y., Völgyi G., Kazsoki A., Sun J., Chen W., Sohajda T., Szente L., Jiang X., Béni S.: Tapentadol enantiomers: Synthesis, physico-chemical characterization and cyclodextrin interactions. J. Pharm. Biomed. Anal. 2013, 88, 594-601.
• 6. Fleming G. J., Robertson S. A.: Assessments of thermal antinociceptive effects of butorphanol and human observer effect on quantitative evaluation of analgesia in green iguanas (Iguana iguana). Am. J. Vet. Res. 2012, 73, 1507-1511.
• 7. Gabrielsson J., Weiner D. (ed): Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Fourth Ed. Swedish Pharmaceutical Press, Stockholm, Sweden 2002, pp. 141-151.
• 8. Giorgi M.: Tramadol vs tapentadol: A new horizon in pain treatment? Am J. Anim. Vet. Sci. 2012, 7, 7-11.
• 9. Giorgi M.: Veterinary pharmacology: Is it still pharmacology’s cinderella? Clin. Exp. Pharmacol. 2012, 2, 103.
• 10. Giorgi M., Del Carlo S., Saccomanni G., Łebkowska-Wieruszewska B., Turini V., Kowalski C.: Biopharmaceutical profile of tramadol in the dog. Vet. Res. Commun. 2009, Suppl. 1, 189-192.
• 11. Giorgi M., Meizler A., Mills P. C.: Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs. Vet. J. 2012, 194, 309-313.
• 12. Giorgi M., Meizler A., Mills P. C.: Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: Development and validation of a new methodology. J. Pharm. Biomed. Anal. 2012, 67-68, 148-153.
• 13. Giorgi M., Mills P. C., Tayari H., Rota S., Breghi G., Briganti A.: Plasma Concentrations of Tapentadol and Clinical Evaluations of a Combination of Tapentadol Plus Sevoflurane for Surgical Anaesthesia and Analgesia in Rabbits Oryctolagus cuniculus) Undergoing Orchiectomy. Isr. J. Vet. Med. 2013, 68, 141-148.
• 14. Giorgi M., Owen H.: Flupirtine: a human drug with potential for use in the veterinary field. Am. J. Anim. Vet. Sci. 2012, 7, 213-217.
• 15. Giorgi M., Saccomanni G., Del Carlo S., Andreoni V.: Pharmacokinetic of tramadol and its major metabolites after intravenous and intramuscular injections in alpacas (Vicugna pacos). J. Camel Pract. Res. 2010, 17, 123-126.
• 16. Giorgi M., Saccomanni G., Del Carlo S., Manera C., Lavy E.: Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles. Vet. J. 2012b, 193, 246-250.
• 17. Giorgi M., Soldani G., Manera C., Ferrarini P., Sgorbini M., Saccomanni G.: Pharmacokinetics of Tramadol and its Metabolites M1, M2 and M5 in Horses Following Intravenous, Immediate Release (Fasted/Fed) and Sustained Release Single Dose Administration. J. Equine Vet. Sci. 2007, 27, 481-488.
• 18. Giorgi M., Yun H.: Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study. Vet. J. 2012, 192, 239-241.
• 19. Greenacre C. B., Schumacher J. P., Talke G.: Comparative antinociception of morphine, butorphanol, and buprenorphine versus saline in the green iguana, Iguana iguana, using electrostimulation. J. Herpetol. Med. Surg. 2006, 16, 88-92.
• 20. Harris L. S., Pierson A. K.: Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 1964, 143, 141-148.
• 21. Hunter R. (red): Zoological pharmacology, [in:] Riviere J. E., Papich M. G. (ed): Veterinary pharmacology and therapeutics, Ninth Ed. Wiley-Blackwell, Ames, IA, USA 2009, pp. 1343-1352.
• 22. Lee H. K., Łebkowska-Wieruszewska B., Kim T. W., Kowaski C. J., Giorgi M.: Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats. Vet. J. 2013, 198, 620-624.
• 23. Mans C., Lahner L. L., Baker B. B., Johnson S. M., Sladky K. K.: Antinociceptive efficacy of buprenorphine and hydromorphone in red-eared slider turtles (Trachemys scripta elegans). J. Zoo Wildlife Med. 2012, 43, 662-665.
• 24. Penick D. N., Spotila J. R., O’Connor M. P., Steyermark A. C., George R. H., Salice C. J., Paladino F. V.: Thermal independence of muscle tissue metabolism in the leatherback turtle, Dermochelys coriacea. Comp. Biochem. Physiol. Part A 1998, 120, 399-403.
• 25. Raffa R. B., Friderichs E., Reimann W., Shank R. P., Codd E. E., Vaught J. L.: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J. Pharmacol. Exp. Ther. 1992, 260, 275-285.
• 26. Riviere J. E., Martin-Jimenez T., Sundlof S. F., Craigmill A. L.: Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species. J. Pharmacol. Exp. Ther. 1997, 20, 453-463.
• 27. Robertson S. A., Lascelles B. D. X., Taylor P. M., Sear J. W.: PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration. J. Vet. Pharmacol. Therap. 2005, 28, 453-460.
• 28. Sladky K. K., Kinney M. E., Johnson S. M.: Analgesic efficacy of butorphanol and morphine in bearded dragons and corn snakes. JAVMA 2008, 233, 267-273.
• 29. Sladky K. K., Kinney M. E., Johnson S. M.: Effects of opioid receptor activation on thermal antinociception in red-eared slider turtles (Trachemys scripta). Am. J. Vet. Res. 2009, 70, 1072-1078.
• 30. Sladky K. K., Miletic V., Paul-Murphy J., Kinney M. E., Dallwig R. K., Johnson S. M.: Analgesic efficacy and respiratory effects of butorphanol and morphine in turtles. JAVMA 2007, 230, 1356-1362.
• 31. Terlinden R., Ossig J., Fliegert F., Gohler K.: Pharmakokinetics, excretion, and metabolism of tapentadol HCl, a novel centrally acting analgesic, in healthy subjects. J. Pain 2006, 7, 26-26.
• 32. Toutain P. L., Lees P.: Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. J. Vet. Pharmacol. Ther. 2004, 27, 467-477.
• 33. Tzschentke T. M., Christoph T., Kögel B., Schiene K., Hennies H. H., Englberger W., Haurand M., Jahnel U., Cremers T. I., Friderichs E.: (-)-(1R,2R)-3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J. Pharmacol. Exp. Ther. 2007, 323, 265-276.
• 34. Tzschentke T.xM., De Vry J., Terlinden R., Hennies H.xH., Lange C., Strassburger W., Haurand M., Kolb J., Schneider J., Buschmann H.: Tapentadol HCl, analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future 2006, 31, 1053-1061.

Uwagi

Rekord w opracowaniu